nafamostat has been researched along with pyrazines in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doi, K; Hayase, N; Ikeda, M; Morimura, N; Moriya, K | 1 |
| Hifumi, T; Ishimatsu, S; Isokawa, S; Otani, N | 1 |
| Inoue, KI; Sagawa, T; Takano, H | 1 |
| Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T | 1 |
| Fätkenheuer, G; Malin, JJ; Rybniker, J; Simonis, A; Theobald, SJ | 1 |
| Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A | 1 |
2 review(s) available for nafamostat and pyrazines
| Article | Year |
|---|---|
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Glucocorticoids; Guanidines; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Recovery of Function; Respiratory Distress Syndrome; Respiratory Insufficiency; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guanidines; Guanine; Humans; Indoles; Lopinavir; Protease Inhibitors; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Virus Internalization; Virus Replication | 2021 |
4 other study(ies) available for nafamostat and pyrazines
| Article | Year |
|---|---|
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.
Topics: Aged; Amides; Benzamidines; Coronavirus Infections; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Female; Guanidines; Humans; Male; Middle Aged; Pyrazines; Treatment Outcome | 2020 |
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Guanidines; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Progression; Guanidines; Humans; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; SARS-CoV-2 | 2020 |
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; COVID-19; Dihydrotestosterone; Disease Progression; Female; Guanidines; Health Personnel; Heparin; Humans; Japan; Metyrapone; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pregnenediones; Pyrazines; SARS-CoV-2; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |